Sanz et al used a simple score to stratify patients with acute promyelocytic leukemia (APML) by risk. The score was derived by a joint study of the Spanish PETHEMA and Italian GIMEMA cooperative groups.
Patient selection: APML treated with an "AIDA-like" regimen (all-trans retinoic acid and idarubicin)
Outcome: relapse-free survival
Parameters:
(1) platelet count in 10^9/L
(2) WBC count in 10^9/L at presentation
Platelet Count
WBC Count
Relapse Risk Group
>= 40 * 10^9/L
<= 10 * 10^9/L
low
< 40 * 10^9/L
<= 10 * 10^9/L
intermediate
NA
> 10 * 10^9/L
high
Risk Group
5 Year Relapse Free Survival
low
100%
intermediate
90%
high risk
74%
To read more or access our algorithms and calculators, please log in or register.
